Skin clearance and route of administration drove treatment choices among 202 patients with psoriasis in the ENCOMPASS-PP discrete choice experiment.
News|Articles|March 17, 2025
AAD 2025 Phase 3 Recap: 7 Trials to Know
Author(s)Patrick Campbell
Fact checked by: Connor Iapoce
A recap of the 7 phase 3 trials presented during the 2025 AAD annual meeting's late-breaking sessions.
Advertisement
Advertisement
An annual showcase of the latest developments and breakthrough for dermatology, the
Related to this article
Oral prifemilast, a PDE4B-selective inhibitor, led to PASI 75 attainment in up to 57.4% of those with psoriasis at week 16 vs 10.8% with placebo.
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
HCPLive recaps October 2026 dermatology highlights, including data in hidradenitis suppurativa, atopic dermatitis, psoriasis, lupus, and alopecia areata.
The FDA updated the risankizumab label to make pretreatment TB evaluation a matter of clinical judgment across all indications, including psoriasis.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Final VALUE data show fewer drug changes with risankizumab vs other biologics over 37 months in patients with psoriasis and comorbid psoriatic arthritis.
In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.
Advertisement
Advertisement